ABSTRACT
Previous genomic efforts on chromosome 9p deletion and duplication syndromes have utilized low resolution strategies (i.e., karyotypes, chromosome microarrays). We present the first large-scale whole-genome sequencing (WGS) study of 100 individuals from families with 9p-related syndromes including 85 unrelated probands through the 9P-ARCH (Advanced Research in Chromosomal Health: Genomic, Phenotypic, and Functional Aspects of 9p-Related syndromes) research network. We analyzed the genomic architecture of these syndromes, highlighting fundamental features and their commonalities and differences across individuals. This work includes a machine-learning model that predicts 9p deletion syndrome from gene copy number estimates using WGS data. Two Late Replicating Regions (LRR1 [a previously un-named human fragile site], LRR2) were identified that contain most structural variant breakpoints in 9p deletion syndrome pointing to replication-based issues in structural variant formation. Furthermore, we show the utility of using WGS information to obtain a comprehensive understanding of 9p-related variation in an individual with complex structural variation where chromothripsis is the likely mechanism. Genes on 9p were prioritized based on statistical assessment of human genomic variation. Furthermore, through application of spatial transcriptomics to embryonic mouse tissue we examined 9p-gene expression in craniofacial and brain development. Through these strategies, we identified 24 important genes for the majority (83%) of individuals with 9p deletion syndrome including AK3, BRD10, CD274, CDC37L1, DMRT1, DMRT2, DMRT3, DOCK8, GLIS3, JAK2, KANK1, KDM4C, PLPP6, PTPRD, PUM3, RANBP6, RCL1, RFX3, RIC1, SLC1A1, SMARCA2, UHRF2, VLDLR, and ZNG1A. Two genes (AK3, ZNG1A) are involved in mitochondrial function and testing of the mitochondrial genome revealed excess copy number in individuals with 9p deletion syndrome. This study presents the most comprehensive genomic analysis of 9p-related syndromes to date, with plans for further expansion through our 9P-ARCH research network.
Competing Interest Statement
The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics Laboratory. N.S., M.M., A.K., M.C., and H.G. are employees of Medgenome Laboratory and K.W. is an employee of Illumina. The affiliation of authors with these entities did not influence the design of the study, data collection, analysis, or interpretation of results. All findings and conclusions presented in this study are solely the responsibility of the authors and do not reflect the views or interests of these affiliations.
Funding Statement
This work was supported by grants from the National Institutes of Health (R00MH117165 to T.N.T., R01MH126933 to T.N.T., R03HD116062 to T.N.T., P50HD103525 to T.N.T.), the Washington University in St. Louis Just-In-Time Core Usage Funding Program (JIT896 to T.N.T., JIT1174 to T.N.T.), the Simons Foundation (734069 to T.N.T.), Washington University in St. Louis laboratory startup funds to T.N.T., and a gift from Leon Eidelman and Sara Israel to the McDonnell Genome Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research participants were consented into the study using an age-appropriate form of consent/assent and in accordance with the Human Research Protection Office at Washington University in St. Louis (IRB #201706062).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Code for DiamondsDenovo is available at https://github.com/TNTurnerLab/DiamondsDenovo. Sequencing data is currently under submission at AnVIL. Denovo-db version 1.8 is available at DOI 10.5281/zenodo.13901295.
